Hydrogen Research Study
← Back to Research Library
Human clinical evidenceHuman Clinical StudyOther or not reported

Randomized, double‐blind, multicenter trial of hydrogen water for Parkinson’s disease

A. Yoritaka, C. Ohtsuka, T. Maeda, M. Hirayama, T. Abe, Hirohisa Watanabe, H. Saiki, G. Oyama, J. Fukae, Y. Shimo, T. Hatano, S. Kawajiri, Y. Okuma, Y. Machida, H. Miwa, C. Suzuki, A. Kazama, M. Tomiyama, T. Kihara, M. Hirasawa, H. Shimura, E. Oda, Mikako Ito, K. Ohno, N. Hattori · Movement Disorders · 2018

Research-use notice

Independent study record

Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.

H2HUBB Research Library branded molecular hydrogen research image
Primary topic Molecular Hydrogen Overview
Evidence type Human clinical evidence
Publication type Human Clinical Study
Hydrogen method Other or not reported

H2HUBB TAKEAWAY

Randomized, double‐blind, multicenter trial of hydrogen water for Parkinson's disease A previous randomized, doubleblind study showed that drinking 1,000 mL of H₂ water per day for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) scores of patients with PD and treated with levodopa. The researchers conducted a longer and larger scale H₂ water trial that also included patients who were not treated with levodopa.

What the Researchers Studied

The study examined 178 participants with PD (93 women and 85 men.

How Molecular Hydrogen Was Used

A previous randomized, doubleblind study showed that drinking 1,000 mL of H₂ water per day for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) scores of patients with PD and treated with levodopa. The researchers conducted a longer and larger scale H₂ water trial that also included patients who were not treated with levodopa.

What the Researchers Found

A previous randomized, doubleblind study showed that drinking 1,000 mL of H₂ water per day for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) scores of patients with PD and treated with levodopa. There were no significant differences in the change in the total UPDRS score from baseline to the 72nd week between the H₂-water group (1.6 ± 14.0 [mean ± standard deviation]) and the placebo water group (0.8 ± 9.6; t test, P =.939; analysis of variance, P =.538; Table 1).

H₂ Mechanisms / Biological Findings

Molecular hydrogen (H₂) water has been shown to reduce oxidative stress and dopaminergic neuronal cell loss in a PD model.

Authors’ Conclusion

A distinct authors’ conclusion was not available in the source material reviewed by H2HUBB.